Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Texas Southwestern Medical Center
Objective one will also include a cross-sectional comparison between HFpEF patients before treatment and non-HFpEF controls matched for age and hypertension
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Group 1: Patients with HFpEF
Diagnosis of heart failure or clear heart failure hospitalization
Stable ejection fraction \> 0.50
Objective evidence of elevated left ventricular filling pressure by one of the following i) pulmonary capillary wedge pressure ≥25 mmHg during supine cardiopulmonary exercise testing or ii) a change in pulmonary capillary wedge pressure of \>15 mmHg during upright exercise
Must be candidates for pharmacological incretin-based directed intensive weight loss therapies as part of their SOC
BMI\>32kg/m2
≥45 years old
Incretin naïve for 6 months
Group 2: Non-HFpEF controls
Adults who do not have heart failure with preserved ejection fraction
Age ≥ 18 years
You may not be if
Group 1
Prior history of reduced ejection fraction (\<50%)
Infiltrative cardiomyopathy
NYHA Class IV chronic heart failure
Left bundle branch block
Unstable coronary artery disease
Uncontrolled arrhythmia
CKD 4 or higher
Currently taking incretin-based drugs (SGL2, GLP1)
Severe valvular heart disease
BMI \> 50kg/m2
Other debilitating illness that would preclude participation
Any contra-indication to MRI
Any contra-indication to muscle biopsies.
Group 2
Age \< 18 years
BMI \> 50 kg/m2
Atrial fibrillation with poorly controlled heart rate
PDE5 inhibitor use
Severe valvular disease
Severe COPD
CKD 4 or higher
Currently taking incretin-based drugs (SGL2, GLP1)
